Chronic Myeloid Leukemia, BCR-ABL1 Positive — Variants & evidence

Loading cancer entity…

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABCB1 Overexpression1
Bafetinib + DasatinibSubstitutes	Predictive	D	Supports Resistance	3	accepted	EID2681 The BCR-ABL1 expressing imatinib-resistant cell line K562/D1-9 overexpresses P-glycoprotein (ABCB1), a known drug membrane transporter. Bafetinib (INNO-406) and dasatinib showed drastically higher IC5… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
ABL1 BCR::ABL D276G1
Imatinib	Predictive	C	Supports Resistance	—	rejected	EID2665 In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC) PMID 15930265 · O'Hare et al., 2005 · Open in CIViC	civic
ABL1 BCR::ABL E255V2
Imatinib	Predictive	C	Supports Resistance	3	rejected	EID7821 One chronic myeloid leukemia patient in chronic phase had a minimal best cytogenetic response to imatinib but became resistant. Bacterial clones generated using peripheral blood RNA later showed the B… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
Imatinib Mesylate	Predictive	D	Supports Resistance	2	rejected	EID6277 In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The E255V mutation in th… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
ABL1 BCR::ABL F311V1
Imatinib Mesylate	Predictive	D	Supports Resistance	2	rejected	EID6249 In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
ABL1 BCR::ABL F317L3
Dasatinib	Predictive	C	Supports Resistance	—	rejected	EID4388 In a retrospective study (of phase 3 clinical trial NCT00481247) of 363 Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia patients in chronic phase, a patient with the F317I mutation in … (full text at CIViC) PMID 26118315 · Hughes et al., 2015 · Open in CIViC	civic
〃	Predictive	C	Supports Resistance	—	rejected	EID4389 In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the F317L or F317V mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=10) were associated with acquired re… (full text at CIViC) PMID 27485109 · Soverini et al., 2016 · Open in CIViC	civic
Imatinib	Predictive	C	Supports Resistance	—	rejected	EID2678 In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations …
ABL1 BCR::ABL F359C1
Imatinib Mesylate	Predictive	D	Supports Resistance	2	rejected	EID6278 In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The F359C mutation in th… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
ABL1 BCR::ABL F486S1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	rejected	EID4572 In a retrospective study of 84 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive (Ph+) chronic myeloid leukemia (in accelerated-phase or with blast crisis) or Ph+ acut… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
ABL1 BCR::ABL L248V3
Dasatinib	Predictive	D	Supports Resistance	2	rejected	EID6281 In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L248V mutation in th… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
Imatinib	Predictive	C	Supports Resistance	—	rejected	EID2643 In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC) PMID 15930265 · O'Hare et al., 2005 · Open in CIViC	civic
Imatinib Mesylate	Predictive	D	Supports Resistance	2	rejected	EID6280 In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L248V mutation in th…
ABL1 BCR::ABL M244V1
Imatinib	Predictive	C	Supports Sensitivity Response	—	rejected	EID2637 In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 BCR::ABL N49S1
Dasatinib	Predictive	C	Does Not Support Resistance	3	rejected	EID7944 Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in accelerated phase had the BCR-ABL1 fusion with G250E/E138G/I242T/K271R/V338M, G250E/E138G/I242T/K271R, G25… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
ABL1 BCR::ABL V186A1
Imatinib	Predictive	C	Supports Resistance	2	rejected	EID7828 One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the V186A secondary variant in 2/12 clones had no response to imatinib before becoming completely resistant. PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
ABL1 BCR::ABL Y253H2
Imatinib	Predictive	C	Supports Resistance	2	rejected	EID7829 One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the Y253H secondary variant in 11/11 clones had complete cytogenetic best cytogenetic response to imatinib before bec… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
Imatinib Mesylate	Predictive	D	Supports Resistance	2	rejected	EID6279 In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The Y253H mutation in th… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
ABL1 C475V2
Bosutinib	Predictive	C	Does Not Support Resistance	1	accepted	EID4768 This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic
Imatinib Mesylate	Predictive	C	Supports Resistance	1	accepted	EID6977 In a study of 39 chronic phase CML patients with BCR-ABL variants, C475V was seen in a single imatinib resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic
ABL1 D363Y1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4699 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 Double Ph1
Imatinib	Predictive	C	Supports Resistance	4	accepted	EID8093 In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic-phase patient had a partial hematologi… (full text at CIViC) PMID 12623848 · Branford et al., 2003 · Open in CIViC	civic
ABL1 E255K2
Dasatinib	Predictive	D	Supports Resistance	2	rejected	EID6283 In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
Imatinib Mesylate	Predictive	C	Supports Resistance	1	rejected	EID7032 In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had E255K mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC	civic
ABL1 E258D1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4694 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 E281K1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4696 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 E450A1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4719 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 E450G1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4437 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 E450K1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4717 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 E453V1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4720 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 E459G2
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4721 In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1fusion positive accelerated phase chronic myeloid leukemia patients, patients with mutations in the AB… (full text at CIViC) PMID 19487385 · Apperley et al., 2009 · Open in CIViC	civic
〃	Predictive	C	Supports Sensitivity Response	—	submitted	EID4722 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 F311I1
Imatinib Mesylate	Predictive	D	Supports Resistance	2	rejected	EID6248 In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
ABL1 F317V1
Dasatinib	Predictive	C	Supports Resistance	—	rejected	EID4536 In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the F317L or F317V mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=10) were associated with acquired re… (full text at CIViC) PMID 27485109 · Soverini et al., 2016 · Open in CIViC	civic
ABL1 F486Y3
Bosutinib	Predictive	C	Supports Resistance	—	submitted	EID4569 In a retrospective study of 118 imatinib-resistant or -intolerant, Philadelphia chromosome BCR-ABL1 fusion positive, chronic myeloid leukemia (chronic phase) patients, no response to dasatinib monothe… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic
〃	Predictive	D	Supports Resistance	—	submitted	EID4570 In an in vitro study, a Ba/F3 murine cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID4573 In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was found to have increased sensitivity to dasatinib treatment, as compa…
ABL1 G250V1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4691 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 G514S1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4725 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 H201L1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4687 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 I242T1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4690 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 I418S1
Dasatinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID4715 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 I418V1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4714 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 K356dup2
Dasatinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID10734 K356dup was observed in an imatinib resistant CML. After switch to dasatinib, the patient regained deep molecular response. Therefore, K356dup seems to be resistant to imatinib and susceptible to dasa… (full text at CIViC) PMID 25998099 · Gniot et al., 2012 · Open in CIViC	civic
Imatinib	Predictive	C	Supports Resistance	3	submitted	EID8107 K356dup was observed in an imatinib resistant CML. After switch to dasatinib, the patient regained deep molecular response. Therefore, K356dup seems to be resistant to imatinib and susceptible to dasa… (full text at CIViC) PMID 25998099 · Gniot et al., 2012 · Open in CIViC	civic
ABL1 L273M1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4695 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 L298V2
Bosutinib	Predictive	C	Does Not Support Resistance	1	accepted	EID4475 In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC	civic
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4476 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
ABL1 L384M1
Imatinib Mesylate	Predictive	D	Supports Resistance	2	rejected	EID6276 In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L384M mutation in th… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
ABL1 M237V1
Dasatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4689 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

ABCB1 Overexpression1

Bafetinib + DasatinibSubstitutes

Predictive

Supports Resistance

accepted

EID2681

The BCR-ABL1 expressing imatinib-resistant cell line K562/D1-9 overexpresses P-glycoprotein (ABCB1), a known drug membrane transporter. Bafetinib (INNO-406) and dasatinib showed drastically higher IC5… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 BCR::ABL D276G1

Imatinib

Predictive

Supports Resistance

—

rejected

EID2665

In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC)

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC

civic

ABL1 BCR::ABL E255V2

Imatinib

Predictive

Supports Resistance

rejected

EID7821

One chronic myeloid leukemia patient in chronic phase had a minimal best cytogenetic response to imatinib but became resistant. Bacterial clones generated using peripheral blood RNA later showed the B… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

civic

Imatinib Mesylate

Predictive

Supports Resistance

rejected

EID6277

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The E255V mutation in th… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

civic

ABL1 BCR::ABL F311V1

Imatinib Mesylate

Predictive

Supports Resistance

rejected

EID6249

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

civic

ABL1 BCR::ABL F317L3

Dasatinib

Predictive

Supports Resistance

—

rejected

EID4388

In a retrospective study (of phase 3 clinical trial NCT00481247) of 363 Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia patients in chronic phase, a patient with the F317I mutation in … (full text at CIViC)

PMID 26118315 · Hughes et al., 2015 · Open in CIViC

civic

〃

Predictive

Supports Resistance

—

rejected

EID4389

In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the F317L or F317V mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=10) were associated with acquired re… (full text at CIViC)

PMID 27485109 · Soverini et al., 2016 · Open in CIViC

civic

Imatinib

Predictive

Supports Resistance

—

rejected

EID2678

ABL1 BCR::ABL F359C1

Imatinib Mesylate

Predictive

Supports Resistance

rejected

EID6278

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

civic

ABL1 BCR::ABL F486S1

Dasatinib

Predictive

Supports Sensitivity Response

—

rejected

EID4572

In a retrospective study of 84 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive (Ph+) chronic myeloid leukemia (in accelerated-phase or with blast crisis) or Ph+ acut… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

civic

ABL1 BCR::ABL L248V3

Dasatinib

Predictive

Supports Resistance

rejected

EID6281

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

civic

Imatinib

Predictive

Supports Resistance

—

rejected

EID2643

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC

civic

Imatinib Mesylate

Predictive

Supports Resistance

rejected

EID6280

ABL1 BCR::ABL M244V1

Imatinib

Predictive

Supports Sensitivity Response

—

rejected

EID2637

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

civic

ABL1 BCR::ABL N49S1

Dasatinib

Predictive

Does Not Support Resistance

rejected

EID7944

Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in accelerated phase had the BCR-ABL1 fusion with G250E/E138G/I242T/K271R/V338M, G250E/E138G/I242T/K271R, G25… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

civic

ABL1 BCR::ABL V186A1

Imatinib

Predictive

Supports Resistance

rejected

EID7828

One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the V186A secondary variant in 2/12 clones had no response to imatinib before becoming completely resistant.

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

civic

ABL1 BCR::ABL Y253H2

Imatinib

Predictive

Supports Resistance

rejected

EID7829

One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the Y253H secondary variant in 11/11 clones had complete cytogenetic best cytogenetic response to imatinib before bec… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

civic

Imatinib Mesylate

Predictive

Supports Resistance

rejected

EID6279

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

civic

ABL1 C475V2

Bosutinib

Predictive

Does Not Support Resistance

accepted

EID4768

This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

civic

Imatinib Mesylate

Predictive

Supports Resistance

accepted

EID6977

In a study of 39 chronic phase CML patients with BCR-ABL variants, C475V was seen in a single imatinib resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

civic

ABL1 D363Y1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4699

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 Double Ph1

Imatinib

Predictive

Supports Resistance

accepted

EID8093

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic-phase patient had a partial hematologi… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

civic

ABL1 E255K2

Dasatinib

Predictive

Supports Resistance

rejected

EID6283

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

civic

Imatinib Mesylate

Predictive

Supports Resistance

rejected

EID7032

In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had E255K mutations

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

civic

ABL1 E258D1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4694

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 E281K1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4696

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 E450A1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4719

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 E450G1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4437

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 E450K1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4717

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 E453V1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4720

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 E459G2

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4721

In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1fusion positive accelerated phase chronic myeloid leukemia patients, patients with mutations in the AB… (full text at CIViC)

PMID 19487385 · Apperley et al., 2009 · Open in CIViC

civic

〃

Predictive

Supports Sensitivity Response

—

submitted

EID4722

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 F311I1

Imatinib Mesylate

Predictive

Supports Resistance

rejected

EID6248

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

civic

ABL1 F317V1

Dasatinib

Predictive

Supports Resistance

—

rejected

EID4536

PMID 27485109 · Soverini et al., 2016 · Open in CIViC

civic

ABL1 F486Y3

Bosutinib

Predictive

Supports Resistance

—

submitted

EID4569

In a retrospective study of 118 imatinib-resistant or -intolerant, Philadelphia chromosome BCR-ABL1 fusion positive, chronic myeloid leukemia (chronic phase) patients, no response to dasatinib monothe… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

civic

〃

Predictive

Supports Resistance

—

submitted

EID4570

In an in vitro study, a Ba/F3 murine cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

civic

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4573

In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was found to have increased sensitivity to dasatinib treatment, as compa…

ABL1 G250V1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4691

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 G514S1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4725

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 H201L1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4687

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 I242T1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4690

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 I418S1

Dasatinib

Predictive

Supports Sensitivity Response

submitted

EID4715

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 I418V1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4714

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 K356dup2

Dasatinib

Predictive

Supports Sensitivity Response

submitted

EID10734

K356dup was observed in an imatinib resistant CML. After switch to dasatinib, the patient regained deep molecular response. Therefore, K356dup seems to be resistant to imatinib and susceptible to dasa… (full text at CIViC)

PMID 25998099 · Gniot et al., 2012 · Open in CIViC

civic

Imatinib

Predictive

Supports Resistance

submitted

EID8107

PMID 25998099 · Gniot et al., 2012 · Open in CIViC

civic

ABL1 L273M1

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4695

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 L298V2

Bosutinib

Predictive

Does Not Support Resistance

accepted

EID4475

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

civic

Dasatinib

Predictive

Supports Sensitivity Response

—

submitted

EID4476

PMID 19779040 · Müller et al., 2009 · Open in CIViC

civic

ABL1 L384M1

Imatinib Mesylate